Tumor necrosis factor receptor superfamily member 8
Details
- Name
- Tumor necrosis factor receptor superfamily member 8
- Synonyms
- CD30
- CD30L receptor
- D1S166E
- Ki-1 antigen
- Lymphocyte activation antigen CD30
- Gene Name
- TNFRSF8
- UniProtKB Entry
- P28908Swiss-Prot
- Organism
- Humans
- NCBI Taxonomy ID
- 9606
- Amino acid sequence
>lcl|BSEQ0006751|Tumor necrosis factor receptor superfamily member 8 MRVLLAALGLLFLGALRAFPQDRPFEDTCHGNPSHYYDKAVRRCCYRCPMGLFPTQQCPQ RPTDCRKQCEPDYYLDEADRCTACVTCSRDDLVEKTPCAWNSSRVCECRPGMFCSTSAVN SCARCFFHSVCPAGMIVKFPGTAQKNTVCEPASPGVSPACASPENCKEPSSGTIPQAKPT PVSPATSSASTMPVRGGTRLAQEAASKLTRAPDSPSSVGRPSSDPGLSPTQPCPEGSGDC RKQCEPDYYLDEAGRCTACVSCSRDDLVEKTPCAWNSSRTCECRPGMICATSATNSCARC VPYPICAAETVTKPQDMAEKDTTFEAPPLGTQPDCNPTPENGEAPASTSPTQSLLVDSQA SKTLPIPTSAPVALSSTGKPVLDAGPVLFWVILVLVVVVGSSAFLLCHRRACRKRIRQKL HLCYPVQTSQPKLELVDSRPRRSSTQLRSGASVTEPVAEERGLMSQPLMETCHSVGAAYL ESLPLQDASPAGGPSSPRDLPEPRVSTEHTNNKIEKIYIMKADTVIVGTVKAELPEGRGL AGPAEPELEEELEADHTPHYPEQETEPPLGSCSDVMLSVEEEGKEDPLPTAASGK
- Number of residues
- 595
- Molecular Weight
- 63746.47
- Theoretical pI
- 5.31
- GO Classification
- Functionstransmembrane signaling receptor activityProcessescellular response to mechanical stimulus / positive regulation of apoptotic process / signal transductionComponentscytoplasm / extracellular exosome
- General Function
- Receptor for TNFSF8/CD30L (PubMed:8391931). May play a role in the regulation of cellular growth and transformation of activated lymphoblasts. Regulates gene expression through activation of NF-kappa-B (PubMed:8999898)
- Specific Function
- protease binding
- Pfam Domain Function
- TNFR_c6 (PF00020)
- Signal Regions
- 1-18
- Transmembrane Regions
- 386-406
- Cellular Location
- Cell membrane
- Gene sequence
>lcl|BSEQ0012428|Tumor necrosis factor receptor superfamily member 8 (TNFRSF8) ATGCGCGTCCTCCTCGCCGCGCTGGGACTGCTGTTCCTGGGGGCGCTACGAGCCTTCCCA CAGGATCGACCCTTCGAGGACACCTGTCATGGAAACCCCAGCCACTACTATGACAAGGCT GTCAGGAGGTGCTGTTACCGCTGCCCCATGGGGCTGTTCCCGACACAGCAGTGCCCACAG AGGCCTACTGACTGCAGGAAGCAGTGTGAGCCTGACTACTACCTGGATGAGGCCGACCGC TGTACAGCCTGCGTGACTTGTTCTCGAGACGACCTCGTGGAGAAGACGCCGTGTGCATGG AACTCCTCCCGTGTCTGCGAATGTCGACCCGGCATGTTCTGTTCCACGTCTGCCGTCAAC TCCTGTGCCCGCTGCTTCTTCCATTCTGTCTGTCCGGCAGGGATGATTGTCAAGTTCCCA GGCACGGCGCAGAAGAACACGGTCTGTGAGCCGGCTTCCCCAGGGGTCAGCCCTGCCTGT GCCAGCCCAGAGAACTGCAAGGAACCCTCCAGTGGCACCATCCCCCAGGCCAAGCCCACC CCGGTGTCCCCAGCAACCTCCAGTGCCAGCACCATGCCTGTAAGAGGGGGCACCCGCCTC GCCCAGGAAGCTGCTTCTAAACTGACGAGGGCTCCCGACTCTCCCTCCTCTGTGGGAAGG CCTAGTTCAGATCCAGGTCTGTCCCCAACACAGCCATGCCCAGAGGGGTCTGGTGATTGC AGAAAGCAGTGTGAGCCCGACTACTACCTGGACGAGGCCGGCCGCTGCACGGCCTGCGTG AGCTGTTCTCGAGATGACCTTGTGGAGAAGACGCCATGTGCATGGAACTCCTCCCGCACC TGCGAATGTCGACCTGGCATGATCTGTGCCACATCAGCCACCAACTCCTGTGCCCGCTGT GTCCCCTACCCAATCTGTGCAGCAGAGACGGTCACCAAGCCCCAGGATATGGCTGAGAAG GACACCACCTTTGAGGCGCCACCCCTGGGGACCCAGCCGGACTGCAACCCCACCCCAGAG AATGGCGAGGCGCCTGCCAGCACCAGCCCCACTCAGAGCTTGCTGGTGGACTCCCAGGCC AGTAAGACGCTGCCCATCCCAACCAGCGCTCCCGTCGCTCTCTCCTCCACGGGGAAGCCC GTTCTGGATGCAGGGCCAGTGCTCTTCTGGGTGATCCTGGTGTTGGTTGTGGTGGTCGGC TCCAGCGCCTTCCTCCTGTGCCACCGGAGGGCCTGCAGGAAGCGAATTCGGCAGAAGCTC CACCTGTGCTACCCGGTCCAGACCTCCCAGCCCAAGCTAGAGCTTGTGGATTCCAGACCC AGGAGGAGCTCAACGCAGCTGAGGAGTGGTGCGTCGGTGACAGAACCCGTCGCGGAAGAG CGAGGGTTAATGAGCCAGCCACTGATGGAGACCTGCCACAGCGTGGGGGCAGCCTACCTG GAGAGCCTGCCGCTGCAGGATGCCAGCCCGGCCGGGGGCCCCTCGTCCCCCAGGGACCTT CCTGAGCCCCGGGTGTCCACGGAGCACACCAATAACAAGATTGAGAAAATCTACATCATG AAGGCTGACACCGTGATCGTGGGGACCGTGAAGGCTGAGCTGCCGGAGGGCCGGGGCCTG GCGGGGCCAGCAGAGCCCGAGTTGGAGGAGGAGCTGGAGGCGGACCATACCCCCCACTAC CCCGAGCAGGAGACAGAACCGCCTCTGGGCAGCTGCAGCGATGTCATGCTCTCAGTGGAA GAGGAAGGGAAAGAAGACCCCTTGCCCACAGCTGCCTCTGGAAAGTGA
- Chromosome Location
- 1
- Locus
- 1p36.22
- External Identifiers
Resource Link UniProtKB ID P28908 UniProtKB Entry Name TNR8_HUMAN GenBank Gene ID AY498860 GeneCard ID TNFRSF8 GenAtlas ID TNFRSF8 HGNC ID HGNC:11923 PDB ID(s) 1D01 KEGG ID hsa:943 IUPHAR/Guide To Pharmacology ID 1877 NCBI Gene ID 943 - General References
- Durkop H, Latza U, Hummel M, Eitelbach F, Seed B, Stein H: Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. Cell. 1992 Feb 7;68(3):421-7. [Article]
- Jung W, Krueger S, Renner C, Gause A, Sahin U, Trumper L, Pfreundschuh M: Opposite effects of the CD30 ligand are not due to CD30 mutations: results from cDNA cloning and sequence comparison of the CD30 antigen from different sources. Mol Immunol. 1994 Dec;31(17):1329-34. [Article]
- Horie R, Ito K, Tatewaki M, Nagai M, Aizawa S, Higashihara M, Ishida T, Inoue J, Takizawa H, Watanabe T: A variant CD30 protein lacking extracellular and transmembrane domains is induced in HL-60 by tetradecanoylphorbol acetate and is expressed in alveolar macrophages. Blood. 1996 Oct 1;88(7):2422-32. [Article]
- Gregory SG, Barlow KF, McLay KE, Kaul R, Swarbreck D, Dunham A, Scott CE, Howe KL, Woodfine K, Spencer CC, Jones MC, Gillson C, Searle S, Zhou Y, Kokocinski F, McDonald L, Evans R, Phillips K, Atkinson A, Cooper R, Jones C, Hall RE, Andrews TD, Lloyd C, Ainscough R, Almeida JP, Ambrose KD, Anderson F, Andrew RW, Ashwell RI, Aubin K, Babbage AK, Bagguley CL, Bailey J, Beasley H, Bethel G, Bird CP, Bray-Allen S, Brown JY, Brown AJ, Buckley D, Burton J, Bye J, Carder C, Chapman JC, Clark SY, Clarke G, Clee C, Cobley V, Collier RE, Corby N, Coville GJ, Davies J, Deadman R, Dunn M, Earthrowl M, Ellington AG, Errington H, Frankish A, Frankland J, French L, Garner P, Garnett J, Gay L, Ghori MR, Gibson R, Gilby LM, Gillett W, Glithero RJ, Grafham DV, Griffiths C, Griffiths-Jones S, Grocock R, Hammond S, Harrison ES, Hart E, Haugen E, Heath PD, Holmes S, Holt K, Howden PJ, Hunt AR, Hunt SE, Hunter G, Isherwood J, James R, Johnson C, Johnson D, Joy A, Kay M, Kershaw JK, Kibukawa M, Kimberley AM, King A, Knights AJ, Lad H, Laird G, Lawlor S, Leongamornlert DA, Lloyd DM, Loveland J, Lovell J, Lush MJ, Lyne R, Martin S, Mashreghi-Mohammadi M, Matthews L, Matthews NS, McLaren S, Milne S, Mistry S, Moore MJ, Nickerson T, O'Dell CN, Oliver K, Palmeiri A, Palmer SA, Parker A, Patel D, Pearce AV, Peck AI, Pelan S, Phelps K, Phillimore BJ, Plumb R, Rajan J, Raymond C, Rouse G, Saenphimmachak C, Sehra HK, Sheridan E, Shownkeen R, Sims S, Skuce CD, Smith M, Steward C, Subramanian S, Sycamore N, Tracey A, Tromans A, Van Helmond Z, Wall M, Wallis JM, White S, Whitehead SL, Wilkinson JE, Willey DL, Williams H, Wilming L, Wray PW, Wu Z, Coulson A, Vaudin M, Sulston JE, Durbin R, Hubbard T, Wooster R, Dunham I, Carter NP, McVean G, Ross MT, Harrow J, Olson MV, Beck S, Rogers J, Bentley DR, Banerjee R, Bryant SP, Burford DC, Burrill WD, Clegg SM, Dhami P, Dovey O, Faulkner LM, Gribble SM, Langford CF, Pandian RD, Porter KM, Prigmore E: The DNA sequence and biological annotation of human chromosome 1. Nature. 2006 May 18;441(7091):315-21. [Article]
- Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7. [Article]
- Lee SY, Park CG, Choi Y: T cell receptor-dependent cell death of T cell hybridomas mediated by the CD30 cytoplasmic domain in association with tumor necrosis factor receptor-associated factors. J Exp Med. 1996 Feb 1;183(2):669-74. [Article]
- Boucher LM, Marengere LE, Lu Y, Thukral S, Mak TW: Binding sites of cytoplasmic effectors TRAF1, 2, and 3 on CD30 and other members of the TNF receptor superfamily. Biochem Biophys Res Commun. 1997 Apr 28;233(3):592-600. [Article]
- Mizushima S, Fujita M, Ishida T, Azuma S, Kato K, Hirai M, Otsuka M, Yamamoto T, Inoue J: Cloning and characterization of a cDNA encoding the human homolog of tumor necrosis factor receptor-associated factor 5 (TRAF5). Gene. 1998 Jan 30;207(2):135-40. [Article]
- Aizawa S, Nakano H, Ishida T, Horie R, Nagai M, Ito K, Yagita H, Okumura K, Inoue J, Watanabe T: Tumor necrosis factor receptor-associated factor (TRAF) 5 and TRAF2 are involved in CD30-mediated NFkappaB activation. J Biol Chem. 1997 Jan 24;272(4):2042-5. [Article]
- Mayya V, Lundgren DH, Hwang SI, Rezaul K, Wu L, Eng JK, Rodionov V, Han DK: Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions. Sci Signal. 2009 Aug 18;2(84):ra46. doi: 10.1126/scisignal.2000007. [Article]
- Rigbolt KT, Prokhorova TA, Akimov V, Henningsen J, Johansen PT, Kratchmarova I, Kassem M, Mann M, Olsen JV, Blagoev B: System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. Sci Signal. 2011 Mar 15;4(164):rs3. doi: 10.1126/scisignal.2001570. [Article]
- Ye H, Park YC, Kreishman M, Kieff E, Wu H: The structural basis for the recognition of diverse receptor sequences by TRAF2. Mol Cell. 1999 Sep;4(3):321-30. [Article]
Associated Data
- Bio-Entities
Bio-Entity Type Tumor necrosis factor receptor superfamily member 8 (Humans) protein primaryTumor necrosis factor receptor (Humans) protein - Drug Relations
Drug Drug group Pharmacological action? Type Actions Details XmAb 2513 investigational unknown target Details Brentuximab vedotin approved, investigational yes target binderantibodyregulator Details Iratumumab investigational unknown target antibodyregulator Details